110.19
-0.28 (-0.26%)
| Previous Close | 110.47 |
| Open | 110.31 |
| Volume | 209,272 |
| Avg. Volume (3M) | 588,570 |
| Market Cap | 7,318,497,792 |
| Price / Sales | 36.63 |
| Price / Book | 44.94 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | -123.28% |
| Operating Margin (TTM) | -143.73% |
| Diluted EPS (TTM) | -2.80 |
| Quarterly Revenue Growth (YOY) | 25.90% |
| Total Debt/Equity (MRQ) | 69.65% |
| Current Ratio (MRQ) | 3.30 |
| Operating Cash Flow (TTM) | -113.49 M |
| Levered Free Cash Flow (TTM) | -96.71 M |
| Return on Assets (TTM) | -51.33% |
| Return on Equity (TTM) | -150.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Rhythm Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -2.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Average | -0.10 |
|
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.65% |
| % Held by Institutions | 103.78% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 142.00 (JMP Securities, 28.87%) | Buy |
| Median | 124.50 (12.99%) | |
| Low | 110.00 (HC Wainwright & Co., -0.17%) | Buy |
| Average | 125.67 (14.05%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 103.64 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 10 Nov 2025 | 114.00 (3.46%) | Buy | 100.30 |
| Needham | 07 Nov 2025 | 120.00 (8.91%) | Buy | 100.30 |
| 04 Nov 2025 | 122.00 (10.72%) | Buy | 104.99 | |
| Goldman Sachs | 17 Oct 2025 | 139.00 (26.15%) | Buy | 110.28 |
| 24 Sep 2025 | 138.00 (25.24%) | Buy | 96.91 | |
| Morgan Stanley | 16 Oct 2025 | 129.00 (17.08%) | Buy | 111.18 |
| 25 Sep 2025 | 122.00 (10.72%) | Buy | 99.14 | |
| HC Wainwright & Co. | 29 Sep 2025 | 110.00 (-0.17%) | Buy | 100.64 |
| JMP Securities | 25 Sep 2025 | 142.00 (28.87%) | Buy | 99.14 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| SHULMAN JOSEPH | - | 111.81 | -9,748 | -1,089,924 |
| Aggregate Net Quantity | -9,748 | |||
| Aggregate Net Value ($) | -1,089,924 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 111.81 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SHULMAN JOSEPH | Officer | 30 Oct 2025 | Automatic sell (-) | 9,748 | 111.81 | 1,089,924 |
| SHULMAN JOSEPH | Officer | 30 Oct 2025 | Option execute | 9,748 | - | - |
| Date | Type | Details |
|---|---|---|
| 07 Nov 2025 | Announcement | Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity |
| 05 Nov 2025 | Announcement | Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program |
| 04 Nov 2025 | Announcement | Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update |
| 21 Oct 2025 | Announcement | Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 |
| 27 Aug 2025 | Announcement | Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences |
| 20 Aug 2025 | Announcement | Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |